The EGALITY study: a confirmatory,randomized, double‐blind study comparing the efficacy,safety and immunogenicity of GP2015, a proposed etanercept biosimilar,vs. the originator product in patients with moderate‐to‐severe chronic plaque‐type psoriasis |
| |
| Authors: | C.E.M. Griffiths D. Thaçi S. Gerdes P. Arenberger G. Pulka K. Kingo J. Weglowska the EGALITY study group N. Hattebuhr J. Poetzl H. Woehling G. Wuerth M. Afonso |
| |
| Affiliation: | 1. Dermatology Centre, Salford Royal Hospital, University of Manchester, Manchester Academic Health Science Centre, Manchester, U.K.;2. Correspondence;3. Christopher Griffiths.;4. E‐mail:;5. Comprehensive Center for Inflammation Medicine, University Hospital Schleswig‐Holstein, Campus Lübeck, Lübeck, Germany;6. Psoriasis‐Center at the Department of Dermatology, Universitaetsklinikum, Schleswig‐Holstein, Campus Kiel, Arnold‐Heller‐Straße 3, Haus 19, 24105 Kiel, Germany;7. Department of Dermatology, Charles University Third Medical Faculty and Faculty Hospital Kralovske Vinohrady, Srobarova 50, Prague 10, 10034 Czech Republic;8. Grazyna Pulka Specjalistyczny Osrodek ‘ALL‐MED’ ul. Sw. Marka 31/IU, ul. Sw. Krzyza 16/14, Krakow, 31‐023 Poland;9. Dermatology Clinic, Tartu University Hospital, Raja 31, Tartu, 50417 Estonia;10. Department of Dermatology, Wojewodzki Szpital Specjalistyczny we Wroclawiu, ul. Kamienskiego 73a, Wroclaw, 51‐124 Poland;11. Global Clinical Development, Biopharmaceuticals, Hexal AG, Industriestraße 25, D 83607 Holzkirchen, Germany |
| |
| Abstract: | ![]()
|
| |
| Keywords: | |
|
|
